Cargando…
MOntelukast as a potential CHondroprotective treatment following Anterior cruciate ligament reconstruction (MOCHA Trial): study protocol for a double-blind, randomized, placebo-controlled clinical trial
BACKGROUND: After anterior cruciate ligament (ACL) reconstruction, patient-reported outcomes are improved 10 years post-surgery; however, cytokine concentrations remain elevated years after surgery with over 80% of those with combined ACL and meniscus injuries having posttraumatic osteoarthritis (PT...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8802473/ https://www.ncbi.nlm.nih.gov/pubmed/35101085 http://dx.doi.org/10.1186/s13063-021-05982-3 |
_version_ | 1784642682541309952 |
---|---|
author | Jacobs, Cale A. Conley, Caitlin E. W. Kraus, Virginia Byers Lansdown, Drew A. Lau, Brian C. Li, Xiaojuan Majumdar, Sharmila Spindler, Kurt P. Lemaster, Nicole G. Stone, Austin V. |
author_facet | Jacobs, Cale A. Conley, Caitlin E. W. Kraus, Virginia Byers Lansdown, Drew A. Lau, Brian C. Li, Xiaojuan Majumdar, Sharmila Spindler, Kurt P. Lemaster, Nicole G. Stone, Austin V. |
author_sort | Jacobs, Cale A. |
collection | PubMed |
description | BACKGROUND: After anterior cruciate ligament (ACL) reconstruction, patient-reported outcomes are improved 10 years post-surgery; however, cytokine concentrations remain elevated years after surgery with over 80% of those with combined ACL and meniscus injuries having posttraumatic osteoarthritis (PTOA) within 10–15 years. The purpose of this multicenter, randomized, placebo-controlled trial is to assess whether a 6-month course of oral montelukast after ACL reconstruction reduces systemic markers of inflammation and biochemical and imaging biomarkers of cartilage degradation. METHODS: We will enroll 30 individuals undergoing primary ACL reconstruction to participate in this IRB-approved multicenter clinical trial. This trial will target those at greatest risk of a more rapid PTOA onset (age range 25–50 with concomitant meniscus injury). Patients will be randomly assigned to a group instructed to take 10 mg of montelukast daily for 6 months following ACL reconstruction or placebo. Patients will be assessed prior to surgery and 1, 6, and 12 months following surgery. To determine if montelukast alters systemic inflammation following surgery, we will compare systemic concentrations of prostaglandin E2, monocyte chemoattractant protein-1, and pro-inflammatory cytokines between groups. We will also compare degradative changes on magnetic resonance imaging (MRI) collected 1 and 12 months following surgery between groups with reductions in early biomarkers of cartilage degradation assessed with urinary biomarkers of type II collagen breakdown and bony remodeling. DISCUSSION: There is a complex interplay between the pro-inflammatory intra-articular environment, underlying bone remodeling, and progressive cartilage degradation. PTOA affects multiple tissues and appears to be more similar to rheumatoid arthritis than osteoarthritis with respect to inflammation. There is currently no treatment to delay or prevent PTOA after ACL injury. Since there is a larger and more persistent inflammatory response after ACL reconstruction than the initial insult of injury, treatment may need to be initiated after surgery, sustained over a period of time, and target multiple mechanisms in order to successfully alter the disease process. This study will assess whether a 6-month postoperative course of oral montelukast affects multiple PTOA mechanisms. Because montelukast administration can be safely sustained for long durations and offers a low-cost treatment option, should it be proven effective in the current trial, these results can be immediately incorporated into clinical practice. TRIAL REGISTRATION: ClinicalTrials.govNCT04572256. Registered on October 1, 2020. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13063-021-05982-3. |
format | Online Article Text |
id | pubmed-8802473 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-88024732022-02-02 MOntelukast as a potential CHondroprotective treatment following Anterior cruciate ligament reconstruction (MOCHA Trial): study protocol for a double-blind, randomized, placebo-controlled clinical trial Jacobs, Cale A. Conley, Caitlin E. W. Kraus, Virginia Byers Lansdown, Drew A. Lau, Brian C. Li, Xiaojuan Majumdar, Sharmila Spindler, Kurt P. Lemaster, Nicole G. Stone, Austin V. Trials Study Protocol BACKGROUND: After anterior cruciate ligament (ACL) reconstruction, patient-reported outcomes are improved 10 years post-surgery; however, cytokine concentrations remain elevated years after surgery with over 80% of those with combined ACL and meniscus injuries having posttraumatic osteoarthritis (PTOA) within 10–15 years. The purpose of this multicenter, randomized, placebo-controlled trial is to assess whether a 6-month course of oral montelukast after ACL reconstruction reduces systemic markers of inflammation and biochemical and imaging biomarkers of cartilage degradation. METHODS: We will enroll 30 individuals undergoing primary ACL reconstruction to participate in this IRB-approved multicenter clinical trial. This trial will target those at greatest risk of a more rapid PTOA onset (age range 25–50 with concomitant meniscus injury). Patients will be randomly assigned to a group instructed to take 10 mg of montelukast daily for 6 months following ACL reconstruction or placebo. Patients will be assessed prior to surgery and 1, 6, and 12 months following surgery. To determine if montelukast alters systemic inflammation following surgery, we will compare systemic concentrations of prostaglandin E2, monocyte chemoattractant protein-1, and pro-inflammatory cytokines between groups. We will also compare degradative changes on magnetic resonance imaging (MRI) collected 1 and 12 months following surgery between groups with reductions in early biomarkers of cartilage degradation assessed with urinary biomarkers of type II collagen breakdown and bony remodeling. DISCUSSION: There is a complex interplay between the pro-inflammatory intra-articular environment, underlying bone remodeling, and progressive cartilage degradation. PTOA affects multiple tissues and appears to be more similar to rheumatoid arthritis than osteoarthritis with respect to inflammation. There is currently no treatment to delay or prevent PTOA after ACL injury. Since there is a larger and more persistent inflammatory response after ACL reconstruction than the initial insult of injury, treatment may need to be initiated after surgery, sustained over a period of time, and target multiple mechanisms in order to successfully alter the disease process. This study will assess whether a 6-month postoperative course of oral montelukast affects multiple PTOA mechanisms. Because montelukast administration can be safely sustained for long durations and offers a low-cost treatment option, should it be proven effective in the current trial, these results can be immediately incorporated into clinical practice. TRIAL REGISTRATION: ClinicalTrials.govNCT04572256. Registered on October 1, 2020. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13063-021-05982-3. BioMed Central 2022-01-31 /pmc/articles/PMC8802473/ /pubmed/35101085 http://dx.doi.org/10.1186/s13063-021-05982-3 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Study Protocol Jacobs, Cale A. Conley, Caitlin E. W. Kraus, Virginia Byers Lansdown, Drew A. Lau, Brian C. Li, Xiaojuan Majumdar, Sharmila Spindler, Kurt P. Lemaster, Nicole G. Stone, Austin V. MOntelukast as a potential CHondroprotective treatment following Anterior cruciate ligament reconstruction (MOCHA Trial): study protocol for a double-blind, randomized, placebo-controlled clinical trial |
title | MOntelukast as a potential CHondroprotective treatment following Anterior cruciate ligament reconstruction (MOCHA Trial): study protocol for a double-blind, randomized, placebo-controlled clinical trial |
title_full | MOntelukast as a potential CHondroprotective treatment following Anterior cruciate ligament reconstruction (MOCHA Trial): study protocol for a double-blind, randomized, placebo-controlled clinical trial |
title_fullStr | MOntelukast as a potential CHondroprotective treatment following Anterior cruciate ligament reconstruction (MOCHA Trial): study protocol for a double-blind, randomized, placebo-controlled clinical trial |
title_full_unstemmed | MOntelukast as a potential CHondroprotective treatment following Anterior cruciate ligament reconstruction (MOCHA Trial): study protocol for a double-blind, randomized, placebo-controlled clinical trial |
title_short | MOntelukast as a potential CHondroprotective treatment following Anterior cruciate ligament reconstruction (MOCHA Trial): study protocol for a double-blind, randomized, placebo-controlled clinical trial |
title_sort | montelukast as a potential chondroprotective treatment following anterior cruciate ligament reconstruction (mocha trial): study protocol for a double-blind, randomized, placebo-controlled clinical trial |
topic | Study Protocol |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8802473/ https://www.ncbi.nlm.nih.gov/pubmed/35101085 http://dx.doi.org/10.1186/s13063-021-05982-3 |
work_keys_str_mv | AT jacobscalea montelukastasapotentialchondroprotectivetreatmentfollowinganteriorcruciateligamentreconstructionmochatrialstudyprotocolforadoubleblindrandomizedplacebocontrolledclinicaltrial AT conleycaitlinew montelukastasapotentialchondroprotectivetreatmentfollowinganteriorcruciateligamentreconstructionmochatrialstudyprotocolforadoubleblindrandomizedplacebocontrolledclinicaltrial AT krausvirginiabyers montelukastasapotentialchondroprotectivetreatmentfollowinganteriorcruciateligamentreconstructionmochatrialstudyprotocolforadoubleblindrandomizedplacebocontrolledclinicaltrial AT lansdowndrewa montelukastasapotentialchondroprotectivetreatmentfollowinganteriorcruciateligamentreconstructionmochatrialstudyprotocolforadoubleblindrandomizedplacebocontrolledclinicaltrial AT laubrianc montelukastasapotentialchondroprotectivetreatmentfollowinganteriorcruciateligamentreconstructionmochatrialstudyprotocolforadoubleblindrandomizedplacebocontrolledclinicaltrial AT lixiaojuan montelukastasapotentialchondroprotectivetreatmentfollowinganteriorcruciateligamentreconstructionmochatrialstudyprotocolforadoubleblindrandomizedplacebocontrolledclinicaltrial AT majumdarsharmila montelukastasapotentialchondroprotectivetreatmentfollowinganteriorcruciateligamentreconstructionmochatrialstudyprotocolforadoubleblindrandomizedplacebocontrolledclinicaltrial AT spindlerkurtp montelukastasapotentialchondroprotectivetreatmentfollowinganteriorcruciateligamentreconstructionmochatrialstudyprotocolforadoubleblindrandomizedplacebocontrolledclinicaltrial AT lemasternicoleg montelukastasapotentialchondroprotectivetreatmentfollowinganteriorcruciateligamentreconstructionmochatrialstudyprotocolforadoubleblindrandomizedplacebocontrolledclinicaltrial AT stoneaustinv montelukastasapotentialchondroprotectivetreatmentfollowinganteriorcruciateligamentreconstructionmochatrialstudyprotocolforadoubleblindrandomizedplacebocontrolledclinicaltrial |